Drug Information

Drug General Information
Drug ID
D0K6UI
Former ID
DPR000165
Drug Name
Galardin
Synonyms
Ilomastat; Galardin MPI; Ilomastat [USAN]; CS 610; GM 6001; CS-610; Ilomastat (USAN/INN); N-[(2R)-2-(Hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan Methylamide; (2R)-N'-hydroxy-N-[(2S)-3-(1H-indol-3-yl)-1-(methylamino)-1-oxopropan-2-yl]-2-(2-methylpropyl)butanediamide; (R)-N(sup 1)-Hydroxy-N-((S)-2-indol-3-yl-1-(methylcarbamoyl)ethyl)-2-isobutylsuccinamide; (S-(R*,S*))-N(sup 4)-Hydroxy-N(sup 1)-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl)-2-(2-methylopropyl)butanediamide
Drug Type
Small molecular drug
Indication Corneal ulcers [ICD9: 370; ICD10:H16.0] Discontinued in Phase 2 [544872]
Therapeutic Class
Antiinflammatory Agents
Company
Glycomed
Structure
Download
2D MOL

3D MOL
Formula
C20H28N4O4
Canonical SMILES
CC(C)CC(CC(=O)NO)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC
InChI
1S/C20H28N4O4/c1-12(2)8-13(10-18(25)24-28)19(26)23-17(20(27)21-3)9-14-11-22-16-7-5-4-6-15(14)16/h4-7,11-13,17,22,28H,8-10H2,1-3H3,(H,21,27)(H,23,26)(H,24,25)/t13-,17+/m1/s1
InChIKey
NITYDPDXAAFEIT-DYVFJYSZSA-N
PubChem Compound ID
132519
PubChem Substance ID
829892, 10243138, 11120050, 11120538, 11121026, 11121715, 11122195, 11147133, 11362833, 11365395, 11367957, 11370897, 11370898, 11373558, 11376119, 12014779, 14878422, 14902905, 17397881, 24902217, 26756835, 26758815, 29310648, 46484604, 46506673, 47364924, 47588747, 48034840, 48258955, 48427395, 50070501, 50071141, 50111444, 50111445, 53790355, 57344178, 79412811, 81060888, 81062449, 81062451, 92310066, 99029951, 99300978, 99302498, 103185416, 103957874, 104377641, 121379601, 124892442, 134340919
Target and Pathway
Target(s) Stromelysin-1 Target Info Inhibitor [528485], [529239]
KEGG Pathway TNF signaling pathway
Transcriptional misregulation in cancer
Rheumatoid arthritis
NetPath Pathway IL1 Signaling Pathway
IL4 Signaling Pathway
PANTHER Pathway Plasminogen activating cascade
CCKR signaling map ST
Pathway Interaction Database Posttranslational regulation of adherens junction stability and dissassembly
p75(NTR)-mediated signaling
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
Reactome Collagen degradation
Degradation of the extracellular matrix
Activation of Matrix Metalloproteinases
Assembly of collagen fibrils and other multimeric structures
EGFR Transactivation by Gastrin
WikiPathways Activation of Matrix Metalloproteinases
Gastrin-CREB signalling pathway via PKC and MAPK
Oncostatin M Signaling Pathway
Matrix Metalloproteinases
References
Ref 544872Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001387)
Ref 528485Blockade of tumor necrosis factor-alpha-converting enzyme improves experimental small intestinal damage by decreasing matrix metalloproteinase-3 production in rats. Scand J Gastroenterol. 2006 Nov;41(11):1320-9.
Ref 529239Novel transcription-factor-like function of human matrix metalloproteinase 3 regulating the CTGF/CCN2 gene. Mol Cell Biol. 2008 Apr;28(7):2391-413.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.